display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L1 - all populationmNSCLC - L1 - PDL1 positivemNSCLC - L2 - PDL1 negative
durvalumab plus tremelimumab MYSTIC ... MYSTIC ... ARCTIC ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons